Johnson & Johnson (NYSE:JNJ) Sets New 52-Week High – Here’s Why

Johnson & Johnson (NYSE:JNJ) reached a new 52-week high during trading on Monday. The company traded as high as $282.33 and last traded at $282.5090, with a volume of 2,259,662 shares changing hands. The stock had previously closed at $276.22.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: ICOTYDE met its Phase 3 primary endpoint in psoriatic arthritis. In biologic-naïve patients, 58% achieved an ACR20 response at Week 16, versus 41% on placebo. The result supports the potential of J&J’s once-daily oral treatment and is a significant late-stage pipeline milestone. Article: Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies
• Positive Sentiment: An investigational prostate-cancer combination showed promising early results. In a Phase 1 study, 11 of 15 patients had PSA reductions of at least 50%, and nearly half had reductions of at least 90%. The regimen’s reported safety and potential for outpatient dosing are encouraging, but results are preliminary as it advances toward Phase 3. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: Nipocalimab adds evidence in Sjögren’s disease. New Phase 2 patient-experience findings highlight relief of dry mouth as a symptom patients value, complementing previously reported results on saliva production. This may help inform the drug’s development, although the update is not a new late-stage efficacy result. Article: Johnson & Johnson announces new Phase 2 nipocalimab study data
• Neutral Sentiment: J&J led a $100 million financing round for a biotech developing psychedelic-inspired medicines for depression. The investment offers exposure to an emerging area but has no clear near-term earnings impact. Article: J&J Backs Psychedelic-Inspired Biotech in $100 Million Round
• Negative Sentiment: One report said ETFs were net sellers of JNJ shares, totaling $68.4 million on Nov. 5. This may signal near-term selling pressure, but a single day of fund flows does not establish a change in the company’s fundamentals. Article: ETFs Are Net Sellers of Johnson & Johnson

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Erste Group Bank downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson Price Performance

The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a market cap of $679.70 billion, a P/E ratio of 42.81, a PEG ratio of 2.73 and a beta of 0.22. The company has a fifty day moving average price of $265.91 and a two-hundred day moving average price of $248.30.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by company insiders.

Institutional Trading of Johnson & Johnson

Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Deutsche Bank AG lifted its holdings in Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Johnson & Johnson by 11.5% during the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after purchasing an additional 1,530,070 shares during the last quarter. Amundi boosted its position in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after buying an additional 148,497 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.